Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F08%3A00103096" target="_blank" >RIV/00843989:_____/08:00103096 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00415-007-0733-2" target="_blank" >http://dx.doi.org/10.1007/s00415-007-0733-2</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00415-007-0733-2" target="_blank" >10.1007/s00415-007-0733-2</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

Popis výsledku v původním jazyce

Background The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and >= 2 clinically silent brain MRI lesions. Methods Subgroups of 468 patients (IFNB-1b: n = 292; placebo: n = 176) were created for demographics, clinical, laboratory, and MRI findings at onset. The 'natural' risk of clinically definite MS (CDMS) over 2 years was estimated by Kaplan Meier statistics in placebo-treated patients; the IFNB-1b treatment effect was analysed by Cox proportional hazards regression. Results The risk of CDMS was increased in placebotreated patients (overall 45 %) if they were younger (< 30 years: 60%), were cerebrospinal fluid (CSF)-positive (49 %), or had received steroid treatment (48 %). MRI parameters implied a higher risk in placebo-treated patients with >= 9 T2-lesions (48%) or >= 1 gadolinium (Gd)-enhancing lesions (52 %). The CDMS risk was highest (75 %) in placebo-treated patients with monofocal disease onset displaying MRI di

Název v anglickém jazyce

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b

Popis výsledku anglicky

Background The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and >= 2 clinically silent brain MRI lesions. Methods Subgroups of 468 patients (IFNB-1b: n = 292; placebo: n = 176) were created for demographics, clinical, laboratory, and MRI findings at onset. The 'natural' risk of clinically definite MS (CDMS) over 2 years was estimated by Kaplan Meier statistics in placebo-treated patients; the IFNB-1b treatment effect was analysed by Cox proportional hazards regression. Results The risk of CDMS was increased in placebotreated patients (overall 45 %) if they were younger (< 30 years: 60%), were cerebrospinal fluid (CSF)-positive (49 %), or had received steroid treatment (48 %). MRI parameters implied a higher risk in placebo-treated patients with >= 9 T2-lesions (48%) or >= 1 gadolinium (Gd)-enhancing lesions (52 %). The CDMS risk was highest (75 %) in placebo-treated patients with monofocal disease onset displaying MRI di

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of neurology

ISSN

0340-5354

e-ISSN

—

Svazek periodika

255

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

8

Strana od-do

480-487

Kód UT WoS článku

000255255300002

EID výsledku v databázi Scopus

—